Table 2.

Select trials of kinase inhibitors in medullary thyroid cancer.

Agent	Molecular targets	Trial phase	Subject population (# of prior lines)	Outcome
				Median PFS (months)	ORR (%)	Reference
Cabozantinib	VEGFR, MET, RET, AX	Phase 3	MTC	11.2 vs 4	28% (58/208)	Elisei et al. 2013
Vandetanib	VEGFR, EGFR, c-KIT, RET	Phase 3	MTC	30.5 vs 19.5	44% (101/231)	Wells et al. 2012
Selpercatinib	RET	Phase 1/2	MTC: treatment naive	NR	73% (64/88) 69% (38/55)	Wirth et al. 2020
			MTC: previously treated
Pralsetinib	RET	Phase 1/2	MTC: treatment naive	NR	71% (15/21) 60% (33/55)	Subbiah et al. 2021a
			MTC: previously treated

MTC, medullary thyroid carcinoma; NR, not reached; ORR, overall response rate; PFS, progression-free survival.